0.10
0.10 (0%)
As of Oct 17, 2023
Athersys, Inc [ATHX]
Source:
Company Overview
Athersys, Inc / New is a biotechnology company that is focused primarily in the field of regenerative medicine. Our MultiStem (invimestrocel) cell therapy, a patented and proprietary allogeneic stem cell product candidate, is our lead platform product and is currently in clinical development.
| Country | United States |
| Headquarters | cleveland, ohio |
| Phone Number | 216-431-9900 |
| Industry | manufacturing |
| CEO | Daniel A. Camardo |
| Website | www.athersys.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-7.8 |
| Net Income | $-3.8 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -21.5% |
| Profit as % of Stockholder Equity | 10.4% |
Management Effectiveness
| Return on Equity | 10.4% |
| Return on Assets | -50.8% |
| Turnover Ratio | 0% |
| EBITA | $-0 |
Balance Sheet and Cash Flow Measures
| Total Assets | $7.4 |
| Total Liabilities | $38.6 |
| Operating Cash Flow | $0 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $0 |
